BMO expects Silence Therapeutics to surge on Zerlasiran partnership, keeps Outperform rating
SLN Stock | USD 7.40 0.59 7.38% |
About 64% of Silence Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Silence Therapeutics PLC suggests that many traders are alarmed. Silence Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Silence Therapeutics PLC. Many technical investors use Silence Therapeutics PLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Silence |
BMO expects Silence Therapeutics to surge on Zerlasiran partnership, keeps Outperform rating
Read at investing.com
Silence Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Silence Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Silence Therapeutics Fundamental Analysis
We analyze Silence Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Silence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Silence Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Silence Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Silence Therapeutics PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Silence Therapeutics stock to make a market-neutral strategy. Peer analysis of Silence Therapeutics could also be used in its relative valuation, which is a method of valuing Silence Therapeutics by comparing valuation metrics with similar companies.
Peers
Silence Therapeutics Related Equities
STTK | Shattuck Labs | 4.00 | ||||
CCCC | C4 Therapeutics | 2.86 | ||||
TARS | Tarsus Pharmaceuticals | 0.02 | ||||
IGMS | IGM Biosciences | 0.63 | ||||
NUVL | Nuvalent | 1.01 | ||||
OPT | Opthea | 1.10 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
MLYS | Mineralys Therapeutics, | 1.43 | ||||
GNFT | Genfit | 1.50 | ||||
CDTX | Cidara Therapeutics | 1.51 | ||||
CTMX | CytomX Therapeutics | 1.65 | ||||
ELYM | Eliem Therapeutics | 1.90 | ||||
RNA | Avidity Biosciences | 2.04 | ||||
PRLD | Prelude Therapeutics | 3.04 | ||||
APLT | Applied Therapeutics | 3.31 | ||||
CNTA | Centessa Pharmaceuticals | 5.65 | ||||
GLUE | Monte Rosa | 7.45 |
Check out Silence Therapeutics Hype Analysis, Silence Therapeutics Correlation and Silence Therapeutics Performance. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.72) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.